Bedinvetmab is an injectable medication that is approved for the treatment of osteoarthritis in dogs in the United States, Canada, Australia, New Zealand, and the European Union.
While this medication has helped several patients, there have been concerns in the veterinary and pet owner communities about potential adverse events.
In the USA, the FDA has even issued a letter to veterinarians raising the concern for adverse events. (see below for links)
The current studies on this medication are funded by the company (Zoetis) and are small in both patient number and duration of evaluation.
Therefore my colleagues (Curtis Dewey, Jennifer Barnhard) and I are performing an independent, unfunded pet owner survey of this medication.
Any person who has a dog that has received this medication is eligible to participate in the study by filling out the brief survey.
Regardless of findings, the manuscript will be promptly submitted to an open access, peer-reviewed journal.
The survey can be found using the link below and will only be available until February 1st, 2025.
If your dog has had Librela, please click on the survey and complete it. Please also share it with your communities.
References:
drbrunke 
Leave a comment